SEC Form 4Coverage since Jun 26, 2026
$FULC insider trading
Over the last 12 months, Fulcrum Therapeutics insiders reported 2 buys totaling $1.5M and 1 sale totaling $66K across SEC Form 4 filings. 33% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $1.5M 2 events
- Sold · 12m
- $66K 1 event
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 33% pre-arranged plans
Side
Price · $FULC · 12Mvia TradingView
Top insiders · 12m
TANG KEVIN—2× · $1.5M
Ezekowitz Alan—1× · $66K
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 17, 2026 | TANG KEVIN10% | ▲ Buy | 167,616 | $3.55 | $595K | +2.4% | 2 tranches · indirect |
| Jul 15, 2026 | TANG KEVIN10% | ▲ Buy | 249,946 | $3.57 | $891K | +3.8% | 4 tranches · indirect |
| Jun 26, 2026 | Ezekowitz AlanD | ▼ Sale | 18,000 | $3.65 | $66K | -62.2% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $FULC feed.